Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
about
CB2 and GPR55 Receptors as Therapeutic Targets for Systemic Immune DysregulationIn vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid systemFunctionally Optimized Neuritogenic Farinosone C Analogs: SAR-Study and Investigations on Their Mode of ActionThe therapeutic potential of cannabinoids for movement disorders.The dual neuroprotective-neurotoxic profile of cannabinoid drugs.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionIncreased 90-kDa ribosomal S6 kinase (Rsk) activity is protective against mutant huntingtin toxicity.Pizotifen Activates ERK and Provides Neuroprotection in vitro and in vivo in Models of Huntington's DiseaseMAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibitionReal-time characterization of cannabinoid receptor 1 (CB1 ) allosteric modulators reveals novel mechanism of action.Prospects for cannabinoid therapies in basal ganglia disorders.Studying neurodegenerative diseases in culture models.Cannabinoids: new promising agents in the treatment of neurological diseases.Application of xCELLigence RTCA Biosensor Technology for Revealing the Profile and Window of Drug Responsiveness in Real Time.Protective Effect of Quercetin against Oxidative Stress-Induced Cytotoxicity in Rat Pheochromocytoma (PC-12) Cells.Gαs signalling of the CB1 receptor and the influence of receptor number.RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.Sensitive and accurate quantification of human leukocyte migration using high-content Discovery-1 imaging system and ATPlite assay.Intracerebroventricular Administration of L-arginine Improves Spatial Memory Acquisition in Triple Transgenic Mice Via Reduction of Oxidative Stress and Apoptosis.
P2860
Q28072822-0219FF36-DF80-4A2D-B220-8E3D29ABD7AFQ28570135-8BC69B02-EA04-44D7-BE2B-A8918F537665Q33636160-A74174AE-9CE6-496B-B198-C13FCD0E045CQ35171113-CFB3804D-CDDE-4C9E-85B5-3DAB939055A3Q35193273-E8B7E031-F2AE-4F54-ABBA-AC17FA72BEE0Q35499568-FC075494-41C9-45B5-8720-7512F2E87749Q35552239-0D386C0A-7D04-472F-86DC-ABB8C15F53E8Q36588268-D8E41D8A-EF41-44AF-A902-A28942C0690BQ37012789-3353AFEC-4F6A-404E-B8B8-DA54F4315D0CQ37237174-6EC96E54-FF49-4853-8702-2C0111B1A302Q37872326-FECE73C8-5D7F-44DB-AD57-363ED543F994Q38165760-A3D46639-4B85-4C12-BCF6-CD805B228026Q38269376-D089E8D7-4A39-4CB5-A467-3DA0A0931EB2Q38884578-C97AD9A9-D041-4A71-94D1-E4CB8FC572D3Q46339528-F2ACBDBF-E586-47B7-815C-D4935ECDC225Q48128574-B7842167-303A-4989-91AC-B479E418FBBAQ48200890-4FE7A843-627B-4C92-A5FA-5AB3002CC010Q48801306-8F2B62E5-5F41-49C4-8946-4862089C5EEBQ54968348-E542098F-DF3B-4F6F-ACCC-2B80752C5F5F
P2860
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Neuroprotective potential of C ...... model of Huntington's disease.
@ast
Neuroprotective potential of C ...... model of Huntington's disease.
@en
Neuroprotective potential of C ...... model of Huntington's disease.
@nl
type
label
Neuroprotective potential of C ...... model of Huntington's disease.
@ast
Neuroprotective potential of C ...... model of Huntington's disease.
@en
Neuroprotective potential of C ...... model of Huntington's disease.
@nl
prefLabel
Neuroprotective potential of C ...... model of Huntington's disease.
@ast
Neuroprotective potential of C ...... model of Huntington's disease.
@en
Neuroprotective potential of C ...... model of Huntington's disease.
@nl
P2860
P50
P1476
Neuroprotective potential of C ...... model of Huntington's disease
@en
P2093
C E Goodfellow
M Dragunow
P2860
P304
P356
10.1111/J.1476-5381.2010.00773.X
P407
P577
2010-06-01T00:00:00Z